[go: up one dir, main page]

EP3787624A4 - Compositions capsule dans capsule d'étéxilate de dabigatran - Google Patents

Compositions capsule dans capsule d'étéxilate de dabigatran Download PDF

Info

Publication number
EP3787624A4
EP3787624A4 EP19848668.0A EP19848668A EP3787624A4 EP 3787624 A4 EP3787624 A4 EP 3787624A4 EP 19848668 A EP19848668 A EP 19848668A EP 3787624 A4 EP3787624 A4 EP 3787624A4
Authority
EP
European Patent Office
Prior art keywords
capsule
compositions
dabigatran etexilate
etexilate
dabigatran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19848668.0A
Other languages
German (de)
English (en)
Other versions
EP3787624A2 (fr
Inventor
Arzu PALANTOKEN
Yildiz Gulkok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2018/06309A external-priority patent/TR201806309A2/tr
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3787624A2 publication Critical patent/EP3787624A2/fr
Publication of EP3787624A4 publication Critical patent/EP3787624A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19848668.0A 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran Withdrawn EP3787624A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2018/06309A TR201806309A2 (tr) 2017-05-10 2018-05-04 Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
PCT/TR2019/050292 WO2020032885A2 (fr) 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran
TR201906582 2019-05-03

Publications (2)

Publication Number Publication Date
EP3787624A2 EP3787624A2 (fr) 2021-03-10
EP3787624A4 true EP3787624A4 (fr) 2022-03-30

Family

ID=69414341

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19848668.0A Withdrawn EP3787624A4 (fr) 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran

Country Status (2)

Country Link
EP (1) EP3787624A4 (fr)
WO (1) WO2020032885A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577067B (zh) * 2021-06-03 2023-08-15 北京福元医药股份有限公司 一种甲磺酸达比加群酯药物制剂

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007710A2 (fr) * 2000-07-20 2002-01-31 Mw Encap Limited Dispositif de delivrance
WO2012001156A2 (fr) * 2010-07-01 2012-01-05 Krka, Tovarna Zdravil, D.D., Novo Mesto Formes pharmaceutiques posologiques orales comprenant de l'étéxilate de dabigatran et ses sels pharmaceutiquement acceptables
WO2014152338A1 (fr) * 2013-03-14 2014-09-25 Kabadi Mohan Administration ciblée d'organismes probiotiques et/ou d'agents thérapeutiques dans le tractus gastro-intestinal
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN104784147A (zh) * 2014-01-20 2015-07-22 成都苑东药业有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
EP2929884A1 (fr) * 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et antagonistes du récepteur de h2
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
WO2016142821A2 (fr) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions contenant un inhibiteur de la thrombine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517843A (ja) * 2011-05-24 2014-07-24 テバ ファーマシューティカル インダストリーズ リミティド 医薬組成物用の圧縮コア
CN110123774A (zh) 2012-02-21 2019-08-16 埃斯蒂维制药有限公司 达比加群酯的口服药物组合物
IN2013CH05441A (fr) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007710A2 (fr) * 2000-07-20 2002-01-31 Mw Encap Limited Dispositif de delivrance
WO2012001156A2 (fr) * 2010-07-01 2012-01-05 Krka, Tovarna Zdravil, D.D., Novo Mesto Formes pharmaceutiques posologiques orales comprenant de l'étéxilate de dabigatran et ses sels pharmaceutiquement acceptables
WO2014152338A1 (fr) * 2013-03-14 2014-09-25 Kabadi Mohan Administration ciblée d'organismes probiotiques et/ou d'agents thérapeutiques dans le tractus gastro-intestinal
CN104784147A (zh) * 2014-01-20 2015-07-22 成都苑东药业有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
EP2929884A1 (fr) * 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et antagonistes du récepteur de h2
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
WO2016142821A2 (fr) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions contenant un inhibiteur de la thrombine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 201675, Derwent World Patents Index; Class A96, AN 2016-637397, XP002789451, BALANAGU H B; BALEBOINA S; BEJAWADA S; CHERUVU R; HILL L A: "Capsule dosage form of direct thrombin inhibitor, useful e.g. for treating deep venous thrombosis and pulmonary embolism, and for reducing risk of stroke and systemic embolism, comprises two types of solid unit dosage forms" *
See also references of WO2020032885A2 *

Also Published As

Publication number Publication date
WO2020032885A3 (fr) 2020-09-24
WO2020032885A2 (fr) 2020-02-13
EP3787624A2 (fr) 2021-03-10

Similar Documents

Publication Publication Date Title
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
EP3695570A4 (fr) Fourniture d'une réponse dans une session
EP3440627A4 (fr) Débrumage et restauration d'images
MA50833A (fr) Compositions et méthodes pour l'édition génique pour l'hémophilie a
EP3437133A4 (fr) Techniques d'empilement de puces et configurations associées
MA52134A (fr) Compositions et procédés pour l'édition génomique
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
EP3455895A4 (fr) Compositions et procédés pour la fabrication d'électrode
IL283942A (en) Tubulysins and protein-tubulysin conjugates
IL260720B (en) Inhibitors of the orexin-1 receptor and compositions comprising the same
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
EP3389673A4 (fr) Procédés et compositions pour l'administration de polynucléotides
MA49006A (fr) Inhibiteurs d'ip6k
EP3380049C0 (fr) Prothèse pour patients porteurs d'entérostomie
DK4233850T3 (da) Kapselformuleringer
EP3463259A4 (fr) Compositions d'écran solaire
EP2956149A4 (fr) Compositions pharmaceutiques destinées au traitement d'helicobacter pylori
IL268905B (en) Phage therapy
EP3960158C0 (fr) Formulations d'amlodipine
EP3864058A4 (fr) Composition photodurcissable
EP3648739A4 (fr) Composition d'injection cutanée
EP3444345A4 (fr) Dérivé d'arnmicro-143
EP3342784A4 (fr) Anticorps entièrement humain inhibant en particulier la connexine 26
EP3720268A4 (fr) Cultivar de stévia '16228013'
EP3713090A4 (fr) Circuit d'interface

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031443900

Ipc: A61K0009480000

A4 Supplementary search report drawn up and despatched

Effective date: 20220225

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4439 20060101ALI20220221BHEP

Ipc: A61K 9/50 20060101ALI20220221BHEP

Ipc: A61K 9/20 20060101ALI20220221BHEP

Ipc: A61K 9/16 20060101ALI20220221BHEP

Ipc: A61K 9/48 20060101AFI20220221BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220927